Download Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Postoperative Radiation for Oral
Cavity Squamous Cell Carcinoma:
The EP
The Difference?
Album
EP
Postoperative Radiation for Oral Cavity
Squamous Cell Carcinoma
• Oral Cavity Cancer is a Surgical Disease
• Use Radiation Postoperatively for
Appropriate Patients
• RT can be used as primary therapy for
small (T1, T2) tumors of the oral cavity.
• Oral tongue
• Floor of Mouth
• Lip
• Best results are with a combination of
external beam radiation and
brachytherapy
Difficult getting enough dose to primary with brachytherapy while still delivering
adequate dose to the regional nodes IJROBP 1990; 18:1287-92.
Brachytherapy complications: soft tissue necrosis, osteonecrosis
Postoperative Radiation for Oral Cavity
Squamous Cell Cancer
•
•
•
•
•
Who needs postop RT?
Definite Indications:
1) Positive Margins
2) Multiple Nodes
3) Extracapsular Extension
Postoperative Radiation for Oral Cavity
Squamous Cell Cancer
•
•
•
•
•
•
Who needs postop RT?
Less certain indications:
1) Lymphovascular space invasion
2) Perineural spread
3) Single encapsulated node +
4) Thick tumors (Tumors 3-9 mm: 44% node+, 7% local
recurrence; >9 mm: 53% subclinical node+, 24% local recurrence Head Neck
2002: 24:513-20)
• 5) Surgeon Vibe
Postoperative Radiation for Oral Cavity
Squamous Cell Cancer
• Why give radiation after surgery?
• RTOG 73-03: locally advanced H&N cancers:
supraglottic larynx, hypopharynx, oral cavity and
oropharynx
• Preop (50 Gy) vs Postop (60 Gy)
• Oral Cavity/oropharynx also had definitive RT
arm (65-70 Gy) followed by surgery if residual
cancer
•
Head Neck Surg 1987;10:19-30
Postoperative Radiation for Oral Cavity
Squamous Cell Cancer
•
•
•
•
RTOG 73-03
277 patients
Ten year follow-up
Improved locoregional control in postoperative
RT arm (65%) vs. preop RT (48%, p=0.04)
• Trend toward improved survival: 38% vs 33%,
p=0.10)
• Surgical and radiation therapy complications
“similar”. IJROBP 1991;20:21-8.
Postoperative Radiation for Oral Cavity
Cancer: Radiation Dose
• RTOG 7303 established 60 Gy as postop RT
dose
• MD Anderson performed prospective
randomized trial evaluating RT dose for 240
patients with resected stage III/IV cancers of oral
cavity, oropharynx, hypopharynx, larynx
• 180 cGy fractions
• Dose ranged from 52.2 Gy to 68.4 Gy
•
IJROBP 1993; 26:3-11.
Postoperative Radiation for Oral Cavity
Cancer: Radiation Dose
• Patients receiving <54 Gy had significantly higher failure rate.
• No dose response beyond 57.6 Gy except for patients with
extracapsular nodal spread.
• +ECE needed at least 63 Gy
• “Clusters” of two or more of the following also predicted increased
risk of failure and need for 63 Gy: oral cavity primary, positive/close
margins, nerve invasion, >2 positive nodes, largest node >3 cm,
treatment delay >6weeks, Zubrod performance status>2
• Moderate to severe complications seen in 7.1%; more if RT dose
>63 Gy
• Dose escalation above 63 Gy “does not appear to improve the
therapeutic ratio”.
Postoperative Radiation for Oral Cavity
Cancer: RT + Chemotherapy
• Two large randomized trials evaluating RT with
or without cisplatin chemotherapy in high-risk
resected head and neck squamous cell cancers.
• EORTC
• RTOG
•
•
NEJM 2004; 350:1945-1952
NEJM 2004: 350:1937-1944
• High risk features: >2 + nodes, +ECE, + margins
(EORTC also included perineural spread and
vascular tumor embolism)
Postoperative Radiation for Oral Cavity
Cancer: RT + Chemotherapy
•
•
•
•
Radiation dose: 60 Gy RTOG; 66 Gy EORTC
Cisplatin 100 mg/m2 days 1, 22, 43 both
334 EORTC + 459 RTOG patients (793 total)
26-27% oral cavity primaries
• In combined analysis, only patients with +ECE
and/or + margins benefited from addition of
cisplatin Head Neck 2005; 27: 843-850
Postoperative Radiation for Oral Cavity
Cancer: RT + Chemotherapy
Postoperative Radiation for Oral Cavity
Cancer: RT + Chemotherapy
Postoperative Radiation for Oral Cavity
Cancer: RT + Chemotherapy
• What’s Next?
• RTOG 0234 evaluated postop chemoRT
(cisplatin or docetaxel) + EGFR inhibitor
cetuximab (Erbitux)
• This phase II study completed but results
are pending
Get to Work!!
Three-Way Tie for Last